[
  {
    "ts": null,
    "headline": "Pfizer Obesity And Hemophilia Advances Spark Fresh Interest In Valuation",
    "summary": "Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than 20 clinical trials, including several focused on this asset. The FDA granted Priority Review for expanded use of HYMPAVZI in hemophilia A or B, potentially widening its eligible patient pool. These updates highlight fresh developments in obesity and hematology that go beyond routine product updates or earnings headlines. For investors tracking NYSE:PFE, these pipeline...",
    "url": "https://finnhub.io/api/news?id=79fcafbbcf56012bf12c87294e0a7ce0ffd42047917468dc113977f20bd76069",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770995613,
      "headline": "Pfizer Obesity And Hemophilia Advances Spark Fresh Interest In Valuation",
      "id": 139085108,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer reported positive Phase 2b results for its monthly GLP-1 obesity drug candidate PF-3944, with plans to run more than 20 clinical trials, including several focused on this asset. The FDA granted Priority Review for expanded use of HYMPAVZI in hemophilia A or B, potentially widening its eligible patient pool. These updates highlight fresh developments in obesity and hematology that go beyond routine product updates or earnings headlines. For investors tracking NYSE:PFE, these pipeline...",
      "url": "https://finnhub.io/api/news?id=79fcafbbcf56012bf12c87294e0a7ce0ffd42047917468dc113977f20bd76069"
    }
  },
  {
    "ts": null,
    "headline": "Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations",
    "summary": "Alnylam has sold off on worries about the short-term health of the TTR market and the company's more aggressive long-term spending plans. Read why ALNY is a Buy.",
    "url": "https://finnhub.io/api/news?id=cd5820ac8514423f502614edb96206e1d9490e6e095792f971b09be778ef0498",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770995221,
      "headline": "Alnylam Hit Hard As Investors Forced To Revise Future Profit Expectations",
      "id": 139088345,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2212827819/image_2212827819.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Alnylam has sold off on worries about the short-term health of the TTR market and the company's more aggressive long-term spending plans. Read why ALNY is a Buy.",
      "url": "https://finnhub.io/api/news?id=cd5820ac8514423f502614edb96206e1d9490e6e095792f971b09be778ef0498"
    }
  },
  {
    "ts": null,
    "headline": "Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds?",
    "summary": "Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of […]",
    "url": "https://finnhub.io/api/news?id=18562af1d81026cb90973382fe8c1b6d5ad47d474314bbb8096da6e2aa1fdcdf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770994655,
      "headline": "Is Pfizer Inc. (PFE) One of the Best Medical Research Stocks to Buy According to Hedge Funds?",
      "id": 139085109,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) is one of the best medical research stocks to buy according to hedge funds. Pfizer Inc. (NYSE:PFE) announced on February 6 that the U.S. Food and Drug Administration accepted and granted Priority Review for its supplemental Biologics License Application for HYMPAVZI® for the expansion of the approved indication to include treatment of […]",
      "url": "https://finnhub.io/api/news?id=18562af1d81026cb90973382fe8c1b6d5ad47d474314bbb8096da6e2aa1fdcdf"
    }
  },
  {
    "ts": null,
    "headline": "Meet the 6.3% Yield Dividend Stock That Could Soar in 2026",
    "summary": "Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.",
    "url": "https://finnhub.io/api/news?id=a347817cad358385e9c877ab8868d291010e54af50ced09264642dd93f39c455",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770983520,
      "headline": "Meet the 6.3% Yield Dividend Stock That Could Soar in 2026",
      "id": 139081226,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.",
      "url": "https://finnhub.io/api/news?id=a347817cad358385e9c877ab8868d291010e54af50ced09264642dd93f39c455"
    }
  },
  {
    "ts": null,
    "headline": "Prices, pipelines and patent cliffs: Inside pharma's big reset",
    "summary": "The new year is shaping up to be a defining year following a dramatic 2025, and one where the impact from last year's developments will crystallize.",
    "url": "https://finnhub.io/api/news?id=df96f791cb216e901bf4bc9085f5f034a80bf7fb4792e673d57c7ebe196d4cb9",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770963193,
      "headline": "Prices, pipelines and patent cliffs: Inside pharma's big reset",
      "id": 139085999,
      "image": "https://image.cnbcfm.com/api/v1/image/108204641-1758911651043-gettyimages-2237192235-nazir-notitle250926_np0Hd.jpeg?v=1758911691&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "The new year is shaping up to be a defining year following a dramatic 2025, and one where the impact from last year's developments will crystallize. ",
      "url": "https://finnhub.io/api/news?id=df96f791cb216e901bf4bc9085f5f034a80bf7fb4792e673d57c7ebe196d4cb9"
    }
  }
]